Literature DB >> 30046580

The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond?

Feihu Xie1, Shi Feng1, Lejia Sun1, Yilei Mao1.   

Abstract

Entities:  

Year:  2018        PMID： 30046580      PMCID： PMC6036058          DOI： 10.21037/hbsn.2018.06.06

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  8 in total

1.  Progress in non-invasive detection of liver fibrosis.

Authors:  Chengxi Li; Rentao Li; Wei Zhang
Journal:  Cancer Biol Med       Date:  2018-05       Impact factor: 4.248

Review 2.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; María Reig; Jordi Bruix
Journal:  Lancet       Date:  2018-01-05       Impact factor: 79.321

3.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Authors:  Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

4.  Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial.

Authors:  Wei Lu; Xin-Li Jin; Chao Yang; Peng Du; Fu-Qiang Jiang; Jun-Peng Ma; Jian Yang; Peng Xie; Zhe Zhang
Journal:  Cancer Biol Ther       Date:  2017-05-26       Impact factor: 4.742

5.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

6.  A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

Authors:  Bruno Sangro; Carlos Gomez-Martin; Manuel de la Mata; Mercedes Iñarrairaegui; Elena Garralda; Pilar Barrera; Jose Ignacio Riezu-Boj; Esther Larrea; Carlos Alfaro; Pablo Sarobe; Juan José Lasarte; Jose L Pérez-Gracia; Ignacio Melero; Jesús Prieto
Journal:  J Hepatol       Date:  2013-03-04       Impact factor: 25.083

7.  Radiographical findings in patients with liver cirrhosis and hepatic encephalopathy.

Authors:  Saleh Elwir; Hassan Hal; Joshua Veith; Ian Schreibman; Zakiyah Kadry; Thomas Riley
Journal:  Gastroenterol Rep (Oxf)       Date:  2015-10-13

8.  Cetirizine-induced hepatotoxicity: case series and review of the literature.

Authors:  Adil Coskun; Irfan Yavasoglu; M Hadi Yasa; Nil Culhaci; Vahit Yukselen
Journal:  Gastroenterol Rep (Oxf)       Date:  2016-08-29
  8 in total
  4 in total

Review 1.  Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.

Authors:  Wei-Xun Chen; Gan-Xun Li; Zheng-Nan Hu; Peng Zhu; Bi-Xiang Zhang; Ze-Yang Ding
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

2.  Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria.

Authors:  Xuqi Sun; Lingling Li; Li Xu; Zhongguo Zhou; Jinbin Chen; Juncheng Wang; Yaojun Zhang; Dandan Hu; Minshan Chen
Journal:  BMC Cancer       Date:  2021-02-09       Impact factor: 4.430

3.  The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.

Authors:  Fei Cao; Yi Yang; Tongguo Si; Jun Luo; Hui Zeng; Zhewei Zhang; Duiping Feng; Yi Chen; Jiaping Zheng
Journal:  Front Oncol       Date:  2021-12-20       Impact factor: 6.244

4.  CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27kip1 Axis.

Authors:  Xin Zhou; Tian-Man Li; Jian-Zhu Luo; Chen-Lu Lan; Zhong-Liu Wei; Tian-Hao Fu; Xi-Wen Liao; Guang-Zhi Zhu; Xin-Ping Ye; Tao Peng
Journal:  J Hepatocell Carcinoma       Date:  2021-11-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.